Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Table 4 Efficacy evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE

Study	Study design (N)		Intravenous chemotherapy simultaneously	Pleural perfusion (N)		Efficacy of therapy								Improvement of SI (N,%)
	Study design (N)			Group 1	Group 2	Group 1				Group 2				Improvement of SI (N,%)
	Group 1	Group 2		Group 1	Group 2	CR	PR	SD	PD	CR	PR	SD	PD	Group 1	Group 2
Yuquan L 2005 [25]	18	18	No	rmhTNF+cisplatin	Cisplatin	5	11	3		2	10	6		–	–
Do W 2005 [20]	31	31	No	rmhTNF+cisplatin	Cisplatin	14	13	4		10	10	11		–	–
Yanhao W 2006 [13]	28	28	No	rmhTNF+cisplatin	Cisplatin	10	13	5		5	9	14		–	–
Zhijun W [26]	53	31	No	rmhTNF+cisplatin	Cisplatin	31	18	4		9	16	6		–	–
Shimeng F 2010 [22]	43	30	No	rmhTNF+cisplatin	Cisplatin	27	12	4		9	8	13		40/43	17/30
Hua Z 2010 [9]	34	24	TP	rmhTNF+cisplatin	Cisplatin	28	3	3		18	2	4		–	–
Xiqiang W 2010 [24]	23	31	No	rmhTNF+cisplatin	Cisplatin	2	18	3		1	17	13		–	–
Haiyan C 2015 [10]	26	27	No	rmhTNF+cisplatin	Cisplatin	6	19	1		4	15	8		–	–
Jin L 2015 [12]	26	29	No	rmhTNF+cisplatin	Cisplatin	16	8	1	1	7	9	8	5	24/26	16/29
Tao H 2016 [23]	30	30	No	rmhTNF+cisplatin	Cisplatin	14	12	4		8	8	14		–	–
Chun W 2016 [19]	32	32	No	rmhTNF+cisplatin	Cisplatin	16	8	8		7	6	19		–	–
Hua Z 2017 [21]	21	18	No	rmhTNF+cisplatin	Cisplatin	2	13	6		1	9	8		–	–

N cases, rmhTNF recombinant mutant human tumor necrosis factor injection, Group 1 rmhTNF injection combined with cisplatin, Group 2 cisplatin alone, CR complete response, PR partial response, SD stable disease, PD progressive disease, TP cisplatin in combination with paclitaxel

ISSN: 1471-2466